The data presented in this study hint that pDCs impairment in melanoma might result from defective TLR/MyD88-dependent signaling (i.e., IRF7 activation) or from a broad perturbation of their metabolic functions (i.e., glycolysis). Here, MYD88 is linked to melanoma.